TGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TG Therapeutics Inc (TGTX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown strong revenue growth and positive developments in its product pipeline, the lack of significant trading signals, mixed financial performance, and neutral trading sentiment suggest waiting for a clearer entry point.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram, indicating an upward trend. RSI is neutral at 62.649, and the stock is trading near its resistance level (R1: 37.654). However, the pre-market price change is minimal (-0.05%), suggesting no significant momentum.
The company presented promising data on BRIUMVI at a major medical conference, highlighting its safety, tolerability, and effectiveness in treating relapsing forms of multiple sclerosis. This could drive increased adoption in the U.S. market.
Despite strong revenue growth (78% YoY), net income and EPS have declined slightly (-1.26% and -6.67% YoY, respectively). Gross margin also dropped by 6.51%, indicating potential cost pressures.
In Q4 2025, revenue increased significantly by 78% YoY to $192.57M, but net income dropped slightly to $23.04M (-1.26% YoY). EPS decreased to 0.14 (-6.67% YoY), and gross margin declined to 80.19% (-6.51% YoY). This mixed performance indicates revenue growth but challenges in profitability.
JPMorgan analyst Brian Cheng recently lowered the price target to $46 from $49 while maintaining an Overweight rating, suggesting confidence in the company's long-term potential despite some near-term adjustments.
